Printer Friendly

ISORAY UNVEILS MILESTONE TREATMENT OF RECTAL CANCER.

IsoRay Inc. has unveiled a milestone in the treatment of rectal cancer using its groundbreaking Cesium-131 (Cs-131) seed sutured mesh for internal radiation therapy.

Drs. J. Steven Johnson of Lewis Hall Singletary Oncology Center and Alan S. Waller of South GA Surgical Associates and the John D. Archbold Memorial Hospital, Thomasville, Georgia, successfully completed the world's first pelvic floor implant using IsoRay Medical's Cesium-131 brachytherapy mesh. Cesium-131 seeded mesh is a form of cancer fighting radiation therapy that is implanted at the time of surgical removal of tumors and immediately attacks the residual cancer cells.

Dr. Johnson commented, When rectal cancers become locally advanced, they recur frequently after surgery. Radiation is therefore performed, but the amount of radiation required to successfully treat the disease is often limited with existing technologies and has the potential to injure the patient. With the Cesium-131 seeded mesh we can get the optimal dose to the area of concern at the time of surgery which we think is a real benefit for the patient.

Recent innovations in cancer surgery have allowed surgeons to remove less healthy tissue than in years past. In these cases, however, radiation therapy becomes a critical addition to the treatment of the cancer. IsoRay Medical supplies multiple radiation based products that can be used at the time of surgery to deliver this needed radiation, ensuring direct irradiation of the cancer-involved target while minimizing the damaging effects of radiation on healthy tissues.

Dr. Johnson added, We have had great success with Cesium- 131 in treating prostate and lung cancers and continue to look for other applications such as these rectal cancers. We can be very confident that a high radiation dose is deposited right where the tumor was, and where cells may still be present. We like the short half-life of Cesium-131 for cancer-controlling reasons and for the convenience that it delivers for the patient.

IsoRay Chairman and CEO Dwight Babcock congratulated the pioneering cancer physicians, We are very pleased to be working with innovative cancer physicians such as Drs. Johnson and Waller. We believe that collaboration between the radiation oncologist and the surgical oncologist offers patients the best possible treatment.

IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).

IsoRay CEO Dwight Babcock says this is just the latest application in cancer treatment representing the continued expansion of use of the Company's pioneering Cesium-131 brachytherapy seeds and liquid isotopes. "We are advancing our domestic and international goal of creating widespread awareness and adoption of Cesium-131. The exceptional results that have been realized in treating such a wide array of cancers are drawing an increasing number of inquiries from the medical community. We believe Cesium- 131's ability to fight cancer and improve the quality of life for the men, women, and children who are battling these devastating cancers distinguishes it from other treatment options."

In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh, and several new implantable devices including the GliaSite radiation therapy system, the world's only liquid radiation balloon catheter device used in the treatment of brain cancer.

About IsoRay

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body.

For more information, visit www.isoray.com or call 509/375-1202.
COPYRIGHT 2013 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Equipment Update
Date:Aug 1, 2013
Words:649
Previous Article:ARAMARK EARNS ISO MEDICAL DEVICE CERTIFICATION.
Next Article:QUANTA'S CDC KIT RECEIVES U.S. FDA CLEARANCE.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters